Abstract:GPR82 is an orphan G protein-coupled receptor (GPCR) that has been implicated in lipid storage in mouse adipocytes. However, the intracellular signaling as well as the specific ligands of GPR82 remain unknown. GPR82 is closely related to GPR34, a GPCR for the bioactive lipid molecule lysophosphatidylserine. In this study, we screened a lipid library using GPR82-transfected cells to search for ligands that act on GPR82. By measuring cyclic adenosine monophosphate levels, we found that GPR82 is an apparently constitutively active GPCR that leads to Gi protein activation. In addition, edelfosine (1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine), an artificial lysophospholipid with a cationic head group that exerts antitumor activity, inhibited the Gi protein activation by GPR82. Two endogenous lysophospholipids with cationic head groups, lysophosphatidylcholine (1-oleoyl-sn-glycero-3-phosphocholine) and lysophosphatidylethanolamine (1-oleoyl-sn-glycero-3-phosphoethanolamine), also exhibited GPR82 inhibitory activity, albeit weaker than edelfosine. Förster resonance energy transfer imaging analysis consistently demonstrated that Gi protein-coupled GPR82 has an apparent constitutive activity that is edelfosine-sensitive. Consistent data were obtained from GPR82-mediated binding analysis of guanosine-5'-O-(3-thiotriphosphate) to cell membranes. Furthermore, in GPR82-transfected cells, edelfosine inhibited insulin-induced extracellular signal-regulated kinase activation, like compounds that function as inverse agonists at other GPCRs. Therefore, edelfosine is likely to act as an inverse agonist of GPR82. Finally, GPR82 expression inhibited adipocyte lipolysis, which was abrogated by edelfosine. Our findings suggested that the cationic lysophospholipids edelfosine, lysophosphatidylcholine and lysophosphatidylethanolamine are novel inverse agonists for Gi-coupled GPR82, which is apparently constitutively active, and has the potential to exert lipolytic effects through GPR82.

Switching Lysophosphatidylserine G Protein-Coupled Receptor Agonists to Antagonists by Acylation of the Hydrophilic Serine Amine

Exploration of LPS2 agonist binding modes using the combination of a new hydrophobic scaffold and homology modeling

Structural basis for ligand recognition and signaling of the lysophosphatidylserine receptors GPR34 and GPR174

Synthesis and Biological Evaluation of Lysophosphatidic Acid Analogues Using Conformational Restriction and Bioisosteric Replacement Strategies

Structural mechanisms of potent lysophosphatidic acid receptor 1 activation by nonlipid basic agonists

Structural basis for lysophosphatidylserine recognition by GPR34

Toward the Three-Dimensional Structure and Lysophosphatidic Acid Binding Characteristics of the LPA(4)/p2y(9)/GPR23 Receptor: a Homology Modeling Study.

Insights into lysophosphatidylserine recognition and Gα12/13-coupling specificity of P2Y10

Elucidating the Binding Mechanism of LPA Species and Analogs in an LPA4 Receptor Homology Model

Human Neuropeptide S Receptor Is Activated via a Gαq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues

Inverse agonism of lysophospholipids with cationic head groups at Gi-coupled receptor GPR82

Cryo-EM structures of human GPR34 enable the identification of selective antagonists

Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Designing Analogs of SAAP-148 with Enhanced Antimicrobial and Anti-LPS Activities

Structure‐Based Design and Synthesis of Lipid A Derivatives to Modulate Cytokine Responses

Development of potent antagonists for formyl peptide receptor 1 based on Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH

Lysophospholipid receptors in drug discovery

Distinct glycerophospholipids potentiate Gsα-activated adenylyl cyclase activity

Specific binding of GPR174 by endogenous lysophosphatidylserine leads to high constitutive Gs signaling

Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule Formyl peptide receptor 2 agonists